News Releases

Lannett Company, Inc. (NYSE: LCI) today announced the closing of the $350 million aggregate principal amount of 7.750% senior secured notes due 2026 (the "Notes") in a private placement to...

Lannett Company, Inc. (NYSE: LCI) (the "Company" or "Lannett") today announced the pricing of the $350 million aggregate principal amount of 7.75% senior secured notes due 2026 (the "Notes") in a...

Lannett Company, Inc. (NYSE: LCI) (the "Company") today announced that it intends to offer, subject to market conditions and other factors, $350 million aggregate principal amount of senior...

Lannett Company, Inc. (NYSE: LCI) today announced the submission of an Abbreviated New Drug Application (ANDA) for Fluticasone propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg...

Lannett Company, Inc. (NYSE: LCI) today announced that it recently received feedback from the U.S. Food and Drug Administration (FDA) regarding biosimilar insulin glargine, a product the company...

Lannett Company, Inc. (NYSE: LCI) today announced that it has added a new co-development agreement for biosimilar insulin aspart with its strategic alliance partners within the HEC Group of...

Lannett Company, Inc. (NYSE: LCI) today announced that it has begun marketing Chlorpromazine Hydrochloride Tablets, USP, 10 mg, 25 mg, 50 mg, 100 mg and 200 mg. The company recently received...

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 second quarter ended December 31, 2020. "For the fiscal 2021 second quarter, net sales exceeded our...

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 second quarter on Wednesday, February 3, 2021, after the market closes. Lannett...

Lannett Company, Inc. (NYSE: LCI) today announced the closing of a $30 million asset-backed revolving credit facility with Wells Fargo Bank, National Association. "Completing this transaction...

Lannett Company, Inc. (NYSE: LCI) today announced that the company used a portion of its existing cash on hand to pay off, in full, the remaining $42 million outstanding balance of its Term A...

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 first quarter ended September 30, 2020. "We view our fiscal 2021 first quarter net sales of $126 million as a...

Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced the launch of the authorized generic of Tirosint® (Levothyroxine Sodium Capsules USP). Lannett entered into an exclusive...

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 first quarter on Wednesday, November 4, 2020, after the market closes. Lannett...

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2020 fourth quarter and full year ended June 30, 2020. "For both the fiscal 2020 full year and fourth quarter, our...

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2020 fourth quarter and full year on Wednesday, August 26, 2020, after the market closes....

Lannett Company, Inc. (NYSE: LCI) today announced the Notice of Proposed Settlement and Dismissal with Prejudice of Derivative Action (the "Notice"), a copy of which is attached hereto as an...

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. distribution agreement for the therapeutically equivalent generic of Flovent® Diskus® (Fluticasone...

Lannett Company, Inc. (NYSE: LCI) today announced the launch of Cediprof, Inc.'s FDA approved Levothyroxine Sodium Tablets USP, under the companies recently announced interim exclusive supply and...

Lannett Company, Inc. (NYSE: LCI) today announced that it will soon launch Levorphanol Tablets 2 mg, a partnered product. Lannett entered into an exclusive U.S. distribution agreement for...

Lannett Company, Inc. (NYSE: LCI) today announced that it has launched Mexiletine Hydrochloride Capsules 150 mg, 200 mg and 250 mg, a partnered product. Mexiletine Hydrochloride Capsules is the...

Lannett Company, Inc. (NYSE: LCI) and Cediprof, Inc., a part of the Neolpharma Pharmaceutical Group family of companies, today said that the companies have entered into an interim exclusive supply...

Lannett Company, Inc. (NYSE: LCI) today announced a restructuring and cost savings plan. The initiatives include consolidating the research and development (R&D) function into a single location in...

Lannett Company, Inc. (NYSE: LCI) today said that representatives from the company spoke with and received guidance from the U.S. Food and Drug Administration (FDA) on the clinical advancement...

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2020 third quarter ended March 31, 2020. "I am incredibly proud of the effort and dedication of all of our...